SCHEMBL6523583

SCHEMBL6523583

O=C(CN1CCC(Nc2ccnc3[nH]c(=O)c4ccccc4c23)CC1)NC1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
DRD4 P21917 1/20 0.44
PARP1 P09874 7/20 0.44
KDM4E B2RXH2 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44
TSHR P16473 3/20 0.43
MAPK1 P28482 1/20 0.43
AURKA O14965 2/20 0.43
AURKB Q96GD4 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6530755 0.99 ALDH1A1 (0.49) ALDH1A1DRD4PARP1KDM4EHSD17B10
SCHEMBL6530953 0.95 AURKA (0.45) ALDH1A1PARP1AURKAAURKB
SCHEMBL12846726 0.88 AURKA (0.40) ALDH1A1PARP1AURKAAURKB
SCHEMBL6521959 0.86 AURKA (0.51) PARP1AURKAAURKB
SCHEMBL6521353 0.85 MEN1 (0.53) DRD4PARP1AURKAAURKB
SCHEMBL6522337 0.84 AURKA (0.55) ALDH1A1DRD4PARP1KDM4EAURKA
SCHEMBL6532315 0.84 TLR9 (0.44) PARP1AURKAAURKB
SCHEMBL6526943 0.82 NPC1 (0.49) PARP1TSHRAURKA
SCHEMBL6522974 0.81 MAPK1 (0.52) ALDH1A1PARP1MAPK1AURKAAURKB
SCHEMBL6532672 0.81 PARP1 (0.54) ALDH1A1DRD4PARP1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 ALDH1A1 4501/4885DRD4 4351/4885PARP1 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.